Risk of hepatitis C virus transmission from patients to surgeons: model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow

D Thorburn, K Roy, S O Cameron, J Johnston, S Hutchinson, E A B McCruden, P R Mills, D J Goldberg

Background: The risk of a surgeon acquiring the hepatitis C virus (HCV) through occupational exposure is dependant on the prevalence of HCV infection in the patient population, the probability of a percutaneous injury transmitting HCV, and the incidence of percutaneous injury during surgery.

Aims: To estimate the prevalence of HCV infection in the adult surgical patient population in North Glasgow and thereafter estimate the risk of HCV transmission to surgeons through occupational exposure.

Methods: The prevalence of HCV infection was estimated through the unlinked anonymous testing of samples from male surgical patients, aged 16–49 years, in two North Glasgow hospitals from 1996 to 1997, and adjusting these data for age and sex. Using published estimates of the incidence of percutaneous injury during surgery and percutaneous injury transmitting HCV, the risk of occupational transmission of HCV to surgeons was then derived.

Results: The estimated prevalence of anti-HCV infection for all adult patients in the two hospitals combined was 1.4% (cardiothoracic/cardiology 0.8%, orthopaedics/rheumatology 1.4%, general surgery/ENT 2.0%). The estimated probability of HCV transmission from an HCV infected patient to an uninfected surgeon was 0.001–0.032% per annum (0.035–1.12% risk over a 35 year professional career).

Conclusions: The risk of an individual surgeon acquiring HCV through occupational exposure is low, even in an area with an extremely high prevalence of HCV among its injecting drug using population. Surgeons however should be encouraged to observe universal precautions and present for assessment after needlestick injuries to protect themselves and their patients from this insidious infection.

Methods

Setting
This study was performed in the Greater Glasgow Health Board area, which incorporates the largest city in Scotland with a population of 904 000 in 2000. Glasgow has an estimated 7500 current injecting drug users of whom approximately 60% are infected with HCV. Patients attending the hospitals (Glasgow Royal Infirmary and Stobhill General Hospital) serving the northern and eastern sectors of the city (population 331 000 (37%)) had been studied as part of an unlinked anonymous programme of human immunodeficiency virus (HIV) surveillance in the West of Scotland. These hospitals were selected because HIV and injecting drug use were more prevalent in their catchment areas than elsewhere in Glasgow.

Study population and procedure
Between January 1992 and December 1997, unlinked anonymous HIV surveillance testing was conducted on residual sera from specimens sent for routine urea and electrolyte testing to the laboratories at Glasgow Royal Infirmary and Stobhill General Hospital. Specimens from male hospital inpatients and outpatients aged 16–49 years who belonged to all clinical specialties, including general practice, were eligible for the study.

Abbreviations: HCV, hepatitis C virus; HCW, health care worker; HBV, hepatitis B virus; HIV, immunodeficiency virus.
Repeat samples submitted within 90 days of the original sample and samples obtained from patients who objected to anonymous testing or were unable to provide informed consent were excluded. Specimens were anonymised by means of a seven digit code which indicated the year and calendar quarter in which the sample was taken, the hospital and specialty requesting the test, and the patient’s age band and sex.¹⁰

For the current study, samples from patients belonging to three of the eight specialty groupings were eligible for HCV antibody testing. These comprised patients undergoing, or with the potential to undergo, surgery: (a) cardiology/cardiac and other vascular surgery, (b) general surgery/ENT/plastic surgery, and (c) rheumatology/orthopaedics. Testing was restricted to samples taken from patients after October 1996, following the UK Health Departments decision to permit unlinked anonymous HCV testing, in addition to that for HIV, on residual samples.

Samples for testing

Sera were initially stored by sequential laboratory number at either 4°C or −20°C on the day of collection in the biochemistry departments. Following routine biochemical testing, residual sera from the study samples were aliquoted into 2.5 ml vials (Sarstedt Ltd, Leicester, UK), labelled with the unique non-identifying code and stored at −20°C. HIV testing was performed at the Regional Virus Laboratory. Samples were thereafter stored at −20°C until HCV testing was performed.

Hepatitis C tests

Initially all HCV testing was performed on pools of five sera with a third generation ELISA (ELISA-3; Ortho Diagnostics, Raritan, New Jersey, USA) using methods that have been validated previously.¹¹ Briefly, 20 µl of each of the five sera to be tested were pooled and mixed thoroughly. Fifty microlitres of this pool were transferred into the test plate (the equivalent of 10 µl of each serum), diluent was added to a total volume of 200 µl, and thereafter testing followed the Ortho ELISA-3 protocol. The final dilution of each individual serum in the pool was 1 in 20 compared with individual testing with a 1 in 11 dilution. The five sera in any reactive pool were then tested individually using the same ELISA-3 (Ortho Diagnostics). Any samples reactive on individual ELISA-3 testing underwent confirmatory testing using a different third generation ELISA (Sanofi Ltd., Northumberland, UK). Any samples that had discrepant results on individual testing by third generation ELISA underwent confirmatory testing by RIBA-3 (Ortho Diagnostics).

Samples were considered positive if they were reactive on individual testing with both third generation ELISAs or if both the initial ELISA-3 and confirmatory RIBA-3 testing were positive.

Modelling of risk of HCV infection through percutaneous injury

The annual risk of a surgeon acquiring HCV infection through percutaneous injury is the product of three key variables: (i) the probability of the patient being infected (HCV prevalence), (ii) the probability of a percutaneous injury from an HCV infected patient transmitting HCV, and (iii) the number of percutaneous needlestick injuries the surgeon experiences.

Table 1: Hepatitis C virus (HCV) antibody positive persons in the Greater Glasgow Health Board area (rates per 100,000 population by sex and age group, reported to 30 June 1997)

<table>
<thead>
<tr>
<th>Sex</th>
<th>5–15 years</th>
<th>16–49 years</th>
<th>50+ years</th>
<th>Not known</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male Positive</td>
<td>162</td>
<td>223</td>
<td>167</td>
<td>1</td>
<td>111</td>
</tr>
<tr>
<td>Male Population Rate</td>
<td>427.2</td>
<td>223.6</td>
<td>167.5</td>
<td>1.1</td>
<td>111.9</td>
</tr>
<tr>
<td>Female Positive</td>
<td>167</td>
<td>223</td>
<td>164</td>
<td>1</td>
<td>112</td>
</tr>
<tr>
<td>Female Population Rate</td>
<td>413.6</td>
<td>222.3</td>
<td>159.4</td>
<td>1.1</td>
<td>112.1</td>
</tr>
<tr>
<td>Not known Positive</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Not known Population Rate</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total Positive</td>
<td>339</td>
<td>446</td>
<td>331</td>
<td>2</td>
<td>838</td>
</tr>
<tr>
<td>Total Population Rate</td>
<td>862.5</td>
<td>448.9</td>
<td>330.8</td>
<td>2.3</td>
<td>838.9</td>
</tr>
</tbody>
</table>

Estimating HCV prevalence

Because HCV testing was performed on specimens from adult males aged between 16 and 49 years, adjustments were required to estimate HCV prevalence among all adults undergoing, or eligible to undergo, surgery. For each of the three different types of surgery, and for all types combined, calculations were performed in four stages. The model was based on...
that previously used by some of the authors to estimate the risk of surgeons acquiring HIV through occupational exposure.\textsuperscript{11}

Stage 1
The prevalence of HCV antibodies among 16–49 year old males was calculated using the following formula:

\[
P^{16-49 \text{ male}} = H^\ddagger/N^\circ
\]

where \(H^\ddagger\) = number of HCV antibody positive males aged 16–49 years and \(N^\circ\) = number of tested males aged 16–49 years.

Stage 2
The estimated HCV prevalence among all adults aged 16–49 years was:

\[
P^{16-49} = (Y \times P^{16-49 \text{ male}})/2
\]

where \(Y\) = factor used to account for the HCV prevalence among all adults aged 16–49. As of 30 June 1997, the rates per 100 000 population of female and male HCV antibody positive diagnosis, aged 16–49 years, from Glasgow were 281.8 and 547.2, respectively (table 1).\textsuperscript{13} Assuming that the rate ratio of 34:66 (1:1.9) was reflected in the surgical patient population aged 16–49 years, the prevalence in the female population (16–49 years) would be 51.5% of that seen in the male population (16–49 years). Thus \(Y = 0.515\).

Stage 3
The estimated prevalence among adults aged over 50 years was calculated using the formula:

\[
P^{50+} = Z \times P^{16-49}
\]

where \(Z\) = the factor used to account for the difference in the prevalence there would be among the older population. As of 30 June 1997, the rates per 100 000 population HCV antibody positive diagnosis, aged 50+ and 16–49 years, were 51.8 and 413.8 (table 1). Assuming that the resulting rate ratio of 0.11:0.89 (1:8) was reflected in the surgical patient population, the prevalence in the older age group would be one eighth of that seen in the younger population. Thus \(Z = 0.125\) (1/8).

Stage 4
The estimated HCV prevalence among all adults was calculated using the following formula:

\[
P^{\alpha \times} = (\alpha \times P^{50+})/1 + \alpha
\]

where \(\alpha\) = the factor used to account for the difference between the numbers of patients aged 16–49 years and 50+ years undergoing, or eligible to undergo, surgery. For adults undergoing surgery during 1997, there were 1.5 persons aged 50+ years for every individual aged 16–49 years (Information and Statistics Division, NHS, Scotland). Thus \(\alpha = 1.5\).

Example
For example, the estimated HCV prevalence for all adults (>16 years) in all three surgical specialties and in both hospitals combined is calculated as follows:

\[\text{Stage 1 (table 2)}\]

\[
P^{16-49} = H^\ddagger/N^\circ = 103/2702 = 3.8\%
\]

\[\text{Stage 2 (table 4)}\]

\[
P^{16-49} = (P^{16-49 \text{ male}} + (Y \times P^{16-49 \text{ male}})/2 = 2.9\%
\]

\[\text{Stage 3}\]

\[
P^{50+} = Z \times P^{16-49} = 0.125 \times 2.9\% = 0.36\%
\]

\[\text{Stage 4}\]

\[
P^{\alpha \times} = (\alpha \times P^{50+})/1 + \alpha = 2.9 + (1.5 \times 0.36\%)/1 + 1.5 = 1.4\%
\]

Probability of percutaneous injury resulting in HCV infection
The average incidence of anti-HCV seroconversion after unintentional needlestick or sharps exposure from an HCV antibody positive source is 1.8% (range 0–7%).\textsuperscript{7} The rate accounts for a majority (75–80%) of anti-HCV positive persons being viraemic and thus infectious.

Percutaneous injuries included in these studies have largely resulted from hollow bore phlebotomy needles without the protective effect of gloves. It is likely that the risk of transmission of HCV after percutaneous exposure relates to the volume of infected blood, as has been observed with HIV.\textsuperscript{15} Two in vitro studies have reported a comparable 86% reduction in the volume of inoculum when a solid suture needle causes injury through a single layer of glove material.\textsuperscript{15} For the purposes of this study, we estimated that the risk of HCV transmission in the surgical setting, where gloves are universally worn and needlestick injuries are mostly from suture needles, would be reduced 10-fold to 0.18%.

Number of percutaneous injuries sustained annually by a surgeon
This number can vary considerably at an individual, specialty, and geographical level. Accordingly, a range of numbers (1, 3, 10, 20

\[\text{Table 2} \] Observed hepatitis C virus (HCV) antibody prevalence for 16–49 year old males undergoing, or eligible to undergo, surgery

<table>
<thead>
<tr>
<th>Specialty group</th>
<th>Glasgow Royal Infirmary (16–49 years)</th>
<th>Stobhill General Hospital (16–49 years)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tested (N(^\circ))</td>
<td>HCV positive (H(^\ddagger))</td>
<td>Prevalence (%)</td>
</tr>
<tr>
<td>Cardiothoracic/ cardiology</td>
<td>632</td>
<td>15</td>
<td>2.4</td>
</tr>
<tr>
<td>Orthopaedics/ rheumatology</td>
<td>647</td>
<td>20</td>
<td>3.1</td>
</tr>
<tr>
<td>General surgery/ENT</td>
<td>679</td>
<td>43</td>
<td>6.3</td>
</tr>
<tr>
<td>Total</td>
<td>1958</td>
<td>78</td>
<td>4.0</td>
</tr>
</tbody>
</table>

H\(^\ddagger\), number of HCV antibody positive males aged 16–49 years; N\(^\circ\), number of males aged 16–49 years HCV antibody tested.

*Glasgow Royal Infirmary versus Stobhill General Hospital, NS.
†General surgery versus orthopaedics, p=0.002
and 9 per year), which are compatible with those observed in European and North American investigations of injuries sustained by surgeons during the 1990s, are incorporated into the analysis.¹

Ethics

Ethics approval for unlinked anonymous testing was obtained from the NHS Trust research ethics committees in both Glasgow hospitals. Statistical analysis of the data was performed using the χ² test and, where indicated, Fisher’s exact test using SigmaStat (SPSS Science Software UK Ltd, Birmingham, UK).

RESULTS

HCV prevalence for males aged 16–49 years (tables 2, 3)

Figure 1 summarises the results of pooled HCV antibody testing and confirmatory testing of samples reactive on individual testing. The overall prevalence of HCV antibodies was 3.8% (103/2702). Observed prevalence rates among males aged 16–49 years varied from 1.6% among cardiothoracic/cardiology patients at Stobhill General Hospital to 6.3% among general surgery/ENT patients at Glasgow Royal Infirmary (table 2). No statistically significant (p<0.05) difference in overall prevalence was observed between the hospitals; however, there was a significant difference in the prevalence observed among specialty groupings (p=0.002).

Table 3 summarises the prevalence of HCV antibodies according to age band of those tested. A significant difference was observed in anti-HCV prevalence among different age groups (p<0.001) (table 3); the highest prevalences were observed in the 25–29 year and 30–34 year age bands (7.1% and 12.0%, respectively). There were no significant differences in the prevalence of anti-HCV among specialties in any of the age bands.

HCV prevalence (estimated) (tables 4, 5)

Estimated rates for all adult men and women in the two hospitals combined are shown by specialty grouping in table 4. Prevalences of 0.8%, 1.4%, and 2.0% were estimated among cardiothoracic/cardiology, orthopaedics/rheumatology, and general surgery/ENT, respectively; for all patients in all specialty groupings the estimated prevalence was 1.4%.

Estimated rates for each five year age band for all adults, displayed in table 5, were derived from the observed prevalences among the tested male patients (table 3) using the equation in stage 2. Peak prevalence rates were observed in the 25–29 year and 30–34 year age bands (5.4% and 9.1%, respectively). There was a significant difference in overall prevalence was observed between the hospitals; however, there was a significant difference in the prevalence observed among specialty groupings (p=0.002).

Annual probability of a surgeon acquiring HCV

A range of probabilities of a surgeon acquiring HCV annually is presented within the matrix (table 6). Probabilities are based on a scale of anti-HCV prevalence from 0.8% to 2% and

Table 3 Observed hepatitis C virus (HCV) antibody prevalence rates for male 16–49 year olds in five year age bands undergoing, or eligible to undergo, surgery

<table>
<thead>
<tr>
<th>Age Band</th>
<th>Cardiothoracic/ cardiology</th>
<th>Orthopaedics/ rheumatology</th>
<th>General surgery/ENT</th>
<th>Total (prevalence %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16–19 years</td>
<td>Tested 11</td>
<td>37</td>
<td>67</td>
<td>115 (0.9%)</td>
</tr>
<tr>
<td>Tested 0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>20–24 years</td>
<td>Tested 30</td>
<td>55</td>
<td>74</td>
<td>159 (2.5%)</td>
</tr>
<tr>
<td>Tested 0</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>25–29 years</td>
<td>Tested 57</td>
<td>120</td>
<td>92</td>
<td>269 (7.1%)</td>
</tr>
<tr>
<td>Tested 3</td>
<td>7</td>
<td>9</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>30–34 years</td>
<td>Tested 81</td>
<td>150</td>
<td>135</td>
<td>366 (12.0%)</td>
</tr>
<tr>
<td>Tested 7</td>
<td>15</td>
<td>22</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>35–39 years</td>
<td>Tested 160</td>
<td>175</td>
<td>145</td>
<td>480 (2.5%)</td>
</tr>
<tr>
<td>Tested 5</td>
<td>2</td>
<td>5</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>40–44 years</td>
<td>Tested 248</td>
<td>226</td>
<td>166</td>
<td>640 (2.8%)</td>
</tr>
<tr>
<td>Tested 3</td>
<td>10</td>
<td>5</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>45–49 years</td>
<td>Tested 298</td>
<td>204</td>
<td>174</td>
<td>676 (7.1%)</td>
</tr>
<tr>
<td>Tested 1</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1 Summary of testing 2702 hospital inpatient and outpatient sera for antibodies to hepatitis C virus (HCV) by Ortho ELISA-3 in pools of five.

www.gutjnl.com
on the number of sustained percutaneous injuries from one to nine (in multiples of three). The three shaded areas highlight the probabilities based on the estimated prevalences calculated for the three specialty groupings (see table 4). For surgeons performing general surgery and sustaining, for example, three percutaneous injuries in 12 months, the annual risk of acquiring HCV would be 1.1 in 10 000 (that is, 0.0018 (HCV prevalence) × 3 (No of percutaneous injuries per annum) × 0.0018 (incidence of HCV seroconversion after needlestick injury)). The corresponding annual risks for those undertaking cardiothoracic and orthopaedic surgery who sustained three injuries would be 0.4 and 0.8 in 10 000, respectively.

DISCUSSION

The estimated annual probability of a surgeon acquiring HCV ranged from 0.001% (one injury and HCV prevalence of 0.8%) to 0.032% (nine injuries and HCV prevalence of 2%), depending on the type of surgery performed and the number of needlestick injuries sustained. If the above range of probability applies consistently across a 35 year working span, the occupational lifetime chance of a surgeon becoming infected with HCV in this area, with a high injecting drug use prevalence and high HCV prevalence among injectors, would range from 0.035% (1 in 2857) to 1.12% (1 in 89). These low rates, even at the improbable upper end of the spectrum, are consistent with a maximum 1.4% occupational lifetime risk, which was generated by the same investigators through an unlinked anonymous HCV testing survey of surgeons in Glasgow; only 1 of 438 surgeons had antibodies to HCV detectable and the source and timing of his/her infection was unknown.3

While the risk of HCV transmission from patient to surgeon is low, both the observed and estimated HCV prevalences among surgical patients indicate that surgeons working in areas of high injecting drug use prevalence and high HCV prevalence among injectors will frequently operate on HCV infected patients (an estimated 1.4% of all surgical patients). Indeed, in Glasgow, the prevalence of HCV among surgical patients is greater than the estimated HCV prevalence of 0.9% in the city’s overall population (unpublished data, SCIEH). Data on the prevalence of HCV among surgical patients elsewhere in the UK do not exist but our findings are consistent with reports from the USA where the prevalence of HCV in such patients exceeded those in the corresponding general populations to which they belong.4 “These observations may be explained by the over representation of intravenous drug users among surgical populations due to the predilection for surgical interventions following injecting related trauma, abscesses, and vascular events.”5 In addition, hospitalised surgical patients may have had medical interventions requiring blood transfusions before blood donor screening for HCV was introduced.

The study model is dependent on local HCV prevalence estimates among patients undergoing surgery and thus the risk probabilities generated by it are unlikely to be appropriate for surgeons practising in areas with different prevalences of injecting drug use and HCV among their injecting drug user populations. The HCV prevalence among all adult patients undergoing, or with the potential to undergo, surgery was

Table 4 Estimated hepatitis C virus (HCV) antibody prevalence rates for all adults undergoing, or eligible to undergo, surgery (Glasgow Royal Infirmary and Stobhill General Hospital combined)

<table>
<thead>
<tr>
<th>Specialty Group</th>
<th>Prevalence in males 16–49 (P&lt;sub&gt;16–49&lt;/sub&gt;)</th>
<th>Prevalence in 16–49 (P&lt;sub&gt;16–49&lt;/sub&gt;)</th>
<th>Prevalence in 50+ (P&lt;sub&gt;50+&lt;/sub&gt;)</th>
<th>Prevalence in all adults (P&lt;sub&gt;adults&lt;/sub&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac/cardiology</td>
<td>2.1%</td>
<td>1.6%</td>
<td>0.2%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Orthopaedics/rheumatology</td>
<td>3.8%</td>
<td>2.9%</td>
<td>0.4%</td>
<td>1.4%</td>
</tr>
<tr>
<td>General surgery/ENT</td>
<td>5.5%</td>
<td>4.2%</td>
<td>0.5%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Total</td>
<td>3.8%</td>
<td>2.9%</td>
<td>0.4%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

Table 5 Estimated hepatitis C virus (HCV) antibody prevalence rates for adults undergoing, or eligible to undergo, surgery analysed in five year age bands (Glasgow Royal Infirmary and Stobhill General Hospital combined)

<table>
<thead>
<tr>
<th>Age band (years)</th>
<th>Males only (observed)</th>
<th>All adults (estimated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16–19</td>
<td>0.9%</td>
<td>0.7%</td>
</tr>
<tr>
<td>20–24</td>
<td>2.5%</td>
<td>1.9%</td>
</tr>
<tr>
<td>25–29</td>
<td>7.1%</td>
<td>5.4%</td>
</tr>
<tr>
<td>30–34</td>
<td>12.0%</td>
<td>9.1%</td>
</tr>
<tr>
<td>35–39</td>
<td>2.5%</td>
<td>1.9%</td>
</tr>
<tr>
<td>40–44</td>
<td>2.8%</td>
<td>2.1%</td>
</tr>
<tr>
<td>45–49</td>
<td>0.7%</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

Table 6 Estimated annual probability of a surgeon acquiring hepatitis C virus (HCV) infection through percutaneous injury (rate per 10 000)

<table>
<thead>
<tr>
<th>Prevalence of HCV among patient populations (%)</th>
<th>1</th>
<th>3</th>
<th>6</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8</td>
<td>0.1</td>
<td>0.4</td>
<td>0.9</td>
<td>1.3</td>
</tr>
<tr>
<td>1.2</td>
<td>0.2</td>
<td>0.5</td>
<td>1.1</td>
<td>1.6</td>
</tr>
<tr>
<td>1.4</td>
<td>0.2</td>
<td>0.6</td>
<td>1.3</td>
<td>1.9</td>
</tr>
<tr>
<td>1.6</td>
<td>0.3</td>
<td>0.8</td>
<td>1.5</td>
<td>2.3</td>
</tr>
<tr>
<td>1.8</td>
<td>0.3</td>
<td>0.9</td>
<td>1.7</td>
<td>2.6</td>
</tr>
<tr>
<td>2.0</td>
<td>0.4</td>
<td>1.1</td>
<td>2.2</td>
<td>3.2</td>
</tr>
</tbody>
</table>

Probabilities are based on a scale of anti-HCV prevalence from 0.8% to 2% and on the number of sustained percutaneous injuries from one to nine (in multiples of three). The three shaded areas highlight the probabilities based on the estimated prevalences calculated for the three specialty groupings (0.8% cardiothoracic/cardiology, 1.4% orthopaedics/rheumatology, 2.0% general surgery/ENT) and for all patients in all specialty groupings (1.4%).
derived through the application of weightings, based on age and sex distributions of diagnosed HCV antibody positive cases in the Greater Glasgow Health Board area, to observed prevalence data on male patients aged 16–49 years. These distributions however may not reflect those for all (diagnosed and undiagnosed) HCV infections in the general populations or, more relevantly, among surgical patients.

The model is also dependent on the incidence of needlestick injury during surgery, the estimates for which emanated from literature relevant to surgical practice in North America and Europe. It is recognised that the incidence of percutaneous exposure varies appreciably among individuals, specialties, and procedures. In a prospective study, performed in operating theatres of Glasgow Royal Infirmary (one of the hospitals included in this study), the incidence of percutaneous exposure was reported to be 15.5 per operator per 1000 operations. This equates to four to five needlestick injuries per year per surgeon, if 250–350 surgical procedures are being performed, a rate which falls within the range included in our model.

To date in the UK, there are no published reports of HCV seroconversions in HCWs following occupational injuries. The absence of reported cases among surgeons likely reflects surgeons’ reluctance to engage in a risk assessment with an occupational health specialist following injury with only an estimated 1 in 20 needlestick injuries reported. Despite the risk of surgeons acquiring HCV from patients being extremely low, those infected, by whatever means, pose a risk to their patients. Several instances of surgeons to patient transmission have now been reported in the UK. Accordingly, the UK Departments of Health introduced guidelines in July 2002 to exclude known HCV infected HCWs from undertaking exposure prone procedures until a sustained virological response to antiviral therapy has been documented. Staff performing exposure prone procedures will not be required to undergo mandatory testing but will be expected to discuss, with occupational health staff, the need for testing if they know or suspect themselves to be infected with HCV.

The risk assessment findings, generated through the use of data, applicable to one of the highest HCV prevalence areas in the UK, should reassure surgeons that the chances of a surfeit needlestick injury resulting in HCV acquisition are extremely low. Nevertheless, surgeons will frequently operate on known and unknown HCV infected persons. In the absence of a vaccine against HCV, it is essential that the risk of infection in the healthcare setting should be minimised through the observance of universal precautions and the development of safer surgical techniques. Furthermore, as early detection and treatment of acute HCV infection after needlestick exposure is associated with sustained viral clearance rates of over 90%, the benefits of surgeons presenting to occupational health departments for HCV testing after sustaining percutaneous injuries are compelling. In so doing, both surgeons and their patients can be protected against the effects of this insidious infection.

ACKNOWLEDGEMENTS

The authors would like to thank Mrs Linda McDonald and Mrs Elaine Murray for identifying, pooling, and testing the sera. In addition, we would like to thank Louise Shaw and Glenn Codere at the Scottish Centre for Infection and Environmental Health who are responsible for the collection of data for, and the management of, the National HCV Register.

Authors’ affiliations

D Thorburn, P R Mills, Gastroenterology Unit, Gartnavel General Hospital, Glasgow, UK

REFERENCES


